<li>acebutolol<p>acebutolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>albiglutide<p>benazepril increases effects of albiglutide by unknown mechanism. Use Caution/Monitor. ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor. .</p></li><li>aldesleukin<p>aldesleukin increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.<span><br><br></span>aldesleukin, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>alfuzosin<p>alfuzosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.<span><br><br></span>benazepril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.<span><br><br></span>alfuzosin increases effects of benazepril by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypotension.</p></li><li>alogliptin<p>alogliptin increases toxicity of benazepril by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of angioedema.</p></li><li>amifostine<p>amifostine increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>aluminum hydroxide<p>aluminum hydroxide decreases effects of benazepril by unspecified interaction mechanism. Use Caution/Monitor. May decrease absorption.</p></li><li>amifostine<p>benazepril increases effects of amifostine by pharmacodynamic synergism. Use Caution/Monitor. When amifostine is used at chemotherapeutic doses, blood pressure lowering medications should be withheld for 24 hr prior to amifostine administration; if blood pressure lowering medication cannot be withheld, amifostine should not be administered.</p></li><li>amiloride<p>benazepril and amiloride both increase  serum potassium. Use Caution/Monitor. Risk of hyperkalemia. Enhanced hypotensive effects.</p></li><li>aminosalicylic acid<p>aminosalicylic acid decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Salicylates may also increase nephrotoxic effects of ACE inhibitors.</p></li><li>amiodarone<p>amiodarone, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>amobarbital<p>amobarbital increases effects of benazepril by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced blood pressure lowering.</p></li><li>amphetamine<p>amphetamine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>amphetamine decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>amphotericin b cholesteryl sulfate<p>amphotericin b cholesteryl sulfate, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>asenapine<p>asenapine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>amphotericin b deoxycholate<p>amphotericin b deoxycholate, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>amphotericin b liposomal<p>amphotericin b liposomal, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>amphotericin b phospholipid complex<p>amphotericin b phospholipid complex, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>amyl nitrite<p>amyl nitrite, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>apomorphine<p>apomorphine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>aprotinin<p>aprotinin decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Aprotinin may diminish  antihypertensive effect of ACE Inhibitors.</p></li><li>aripiprazole<p>aripiprazole, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>arsenic trioxide<p>arsenic trioxide, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>asenapine<p>benazepril increases effects of asenapine by pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>aspirin<p>benazepril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate decreases effects of benazepril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>benazepril, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>atenolol<p>atenolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>avanafil<p>avanafil increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.<span><br><br></span>avanafil increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>axitinib<p>amlodipine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>azathioprine<p>benazepril, azathioprine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of neutropenia.</p></li><li>bendroflumethiazide<p>bendroflumethiazide, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Thiazide-like diuretics may also enhance the nephrotoxic effects of ACE inhibitors.</p></li><li>benperidol<p>benperidol, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.</p></li><li>betaxolol<p>betaxolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>bismuth subsalicylate<p>bismuth subsalicylate decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Salicylates may also increase nephrotoxic effects of ACE inhibitors.</p></li><li>bisoprolol<p>bisoprolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>boceprevir<p>boceprevir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bortezomib<p>bortezomib, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>brexpiprazole<p>brexpiprazole increases toxicity of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>bromocriptine<p>bromocriptine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>bumetanide<p>benazepril, bumetanide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>bupivacaine<p>bupivacaine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>butabarbital<p>butabarbital increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>butalbital<p>butalbital increases toxicity of benazepril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>calcium acetate<p>calcium acetate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium carbonate<p>calcium carbonate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>calcium carbonate decreases effects of benazepril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>calcium chloride<p>calcium chloride decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>canagliflozin<p>benazepril and canagliflozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>calcium citrate<p>calcium citrate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium gluconate<p>calcium gluconate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>carbidopa<p>carbidopa increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.<span><br><br></span>carbidopa increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.</p></li><li>cariprazine<p>cariprazine increases toxicity of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.<span><br><br></span>benazepril increases toxicity of cariprazine by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>carvedilol<p>carvedilol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>celecoxib<p>benazepril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>celiprolol<p>celiprolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>chlorothiazide<p>benazepril, chlorothiazide.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Ehanced hypotensive effects. Increased risk of nephrotoxicity. Monitor blood pressure and renal function.</p></li><li>chlorpropamide<p>benazepril increases effects of chlorpropamide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>chlorthalidone<p>benazepril, chlorthalidone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects. Increased risk of nephrotoxicity. Monitor blood pressure and renal function.</p></li><li>choline magnesium trisalicylate<p>benazepril, choline magnesium trisalicylate.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>benazepril increases toxicity of ciprofloxacin by unknown mechanism. Use Caution/Monitor. ACE Inhibitors may increase arrhythmogenic potential of ciprofloxacin, possibly by increasing serum potassium levels.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased effect of calcium channel blockers may lead to hypotension, edema, decreased HR, and acute kidney injury due to reduced renal blood flow</p></li><li>clevidipine<p>amlodipine and clevidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>clomiphene<p>clomiphene, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>clomipramine<p>clomipramine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>clozapine<p>clozapine increases toxicity of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.<span><br><br></span>benazepril increases toxicity of clozapine by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>cobicistat<p>cobicistat will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conivaptan<p>conivaptan, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>crizotinib<p>crizotinib increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.</p></li><li>crofelemer<p>crofelemer increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclosporine<p>amlodipine increases levels of cyclosporine by unspecified interaction mechanism. Modify Therapy/Monitor Closely. A prospective study in renal transplant recipients averaged a 40% increase in cyclosporine trough levels.<span><br><br></span>benazepril and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. May increase risk of acute renal failure.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>dalteparin<p>dalteparin increases toxicity of benazepril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dexmedetomidine<p>dexmedetomidine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>dextroamphetamine<p>dextroamphetamine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>diazoxide<p>diazoxide increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Diazoxide may enhance the hypotensive effect of antihypertensive agents.</p></li><li>dichlorphenamide<p>dichlorphenamide and amlodipine both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>benazepril, diclofenac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>diflunisal<p>benazepril, diflunisal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>digoxin<p>benazepril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>diltiazem<p>amlodipine and diltiazem both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>doxazosin<p>doxazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>drospirenone<p>benazepril and drospirenone both increase  serum potassium. Use Caution/Monitor.</p></li><li>duloxetine<p>duloxetine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>enoxaparin<p>enoxaparin increases toxicity of benazepril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>eplerenone<p>benazepril, eplerenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>epoprostenol<p>epoprostenol, benazepril.
Either decreases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>esmolol<p>esmolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>ethacrynic acid<p>benazepril, ethacrynic acid.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>etodolac<p>benazepril, etodolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>everolimus<p>benazepril, everolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>exenatide injectable solution<p>benazepril increases effects of exenatide injectable solution by Other (see comment). Use Caution/Monitor. 
Comment: ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor. .</p></li><li>exenatide injectable suspension<p>benazepril increases effects of exenatide injectable suspension by Other (see comment). Use Caution/Monitor. 
Comment: ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor.</p></li><li>felodipine<p>amlodipine and felodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>fenoprofen<p>benazepril, fenoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ferric gluconate<p>benazepril increases toxicity of ferric gluconate by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>ferrous gluconate<p>benazepril increases toxicity of ferrous gluconate by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Benazepril may enhance adverse/toxic effects of ferrous gluconate.</p></li><li>flibanserin<p>amlodipine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>flurbiprofen<p>benazepril, flurbiprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>furosemide<p>benazepril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>glimepiride<p>benazepril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>glipizide<p>benazepril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypogylcemic effects.</p></li><li>gliquidone<p>benazepril increases effects of gliquidone by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>glyburide<p>benazepril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>gold sodium thiomalate<p>benazepril, gold sodium thiomalate. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Combo of ACE inhibitors and injectable gold has caused rare cases of nitritoid reaction (flushing, N/V, hypot'n).</p></li><li>heparin<p>heparin increases toxicity of benazepril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>hydrochlorothiazide<p>benazepril increases toxicity of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects; increased risk of nephrotoxicity.</p></li><li>ibuprofen<p>benazepril, ibuprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>icatibant<p>icatibant decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Icatibant has potential to have a pharmacodynamic interaction with ACE inhibitors where it may attenuate the antihypertensive effect of ACE inhibitors.</p></li><li>iloperidone<p>iloperidone increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.<span><br><br></span>iloperidone increases toxicity of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.<span><br><br></span>benazepril increases toxicity of iloperidone by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>iloprost<p>iloprost, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>indapamide<p>indapamide, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Thiazide-like diuretics may also enhance the nephrotoxic effects of ACE inhibitors.</p></li><li>indomethacin<p>benazepril, indomethacin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>insulin aspart<p>benazepril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects. Monitor blood glucose.</p></li><li>insulin degludec<p>benazepril, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin degludec/insulin aspart<p>benazepril, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin detemir<p>benazepril increases effects of insulin detemir by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin glargine<p>benazepril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin glulisine<p>benazepril increases effects of insulin glulisine by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin inhaled<p>benazepril, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin lispro<p>benazepril increases effects of insulin lispro by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin nph<p>benazepril increases effects of insulin nph by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>insulin regular human<p>benazepril increases effects of insulin regular human by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>isocarboxazid<p>isocarboxazid, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>isoflurane<p>isoflurane, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>isosorbide dinitrate<p>isosorbide dinitrate, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>isradipine<p>amlodipine and isradipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoprofen<p>benazepril, ketoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac<p>benazepril, ketorolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac intranasal<p>benazepril, ketorolac intranasal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>labetalol<p>labetalol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>lacidipine<p>amlodipine and lacidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>lanthanum carbonate<p>lanthanum carbonate decreases levels of benazepril by cation binding in GI tract. Use Caution/Monitor. Administer ACE inhibitor at least 2 hr before or after lanthanum.</p></li><li>lercanidipine<p>amlodipine and lercanidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>lesinurad<p>lesinurad decreases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levodopa<p>levodopa increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.<span><br><br></span>benazepril, levodopa.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.<span><br><br></span>levodopa increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>liraglutide<p>benazepril increases effects of liraglutide by unknown mechanism. Use Caution/Monitor. ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor. .</p></li><li>lomitapide<p>amlodipine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>lisdexamfetamine<p>lisdexamfetamine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>lithium<p>benazepril increases toxicity of lithium by unknown mechanism. Use Caution/Monitor. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule. Monitor lithium levels.</p></li><li>lurasidone<p>lurasidone increases effects of amlodipine by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.<span><br><br></span>lurasidone increases effects of benazepril by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>magnesium salicylate<p>benazepril, magnesium salicylate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, elderly or volume depleted individuals.</p></li><li>maraviroc<p>maraviroc, amlodipine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.</p></li><li>maraviroc<p>maraviroc, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.</p></li><li>meclofenamate<p>benazepril, meclofenamate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mefenamic acid<p>benazepril, mefenamic acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mefloquine<p>mefloquine increases levels of amlodipine by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia.</p></li><li>meloxicam<p>benazepril, meloxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mephobarbital<p>mephobarbital, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>metformin<p>benazepril increases toxicity of metformin by unspecified interaction mechanism. Use Caution/Monitor. Increases risk for hypoglycemia and lactic acidosis.</p></li><li>methamphetamine<p>methamphetamine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>methohexital<p>methohexital increases toxicity of benazepril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>methyclothiazide<p>benazepril, methyclothiazide.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects; increased risk of nephrotoxicity.</p></li><li>methylphenidate<p>methylphenidate decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effect of benazepril.</p></li><li>metolazone<p>metolazone, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Thiazide-like diuretics may also enhance the nephrotoxic effects of ACE inhibitors.</p></li><li>metoprolol<p>metoprolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>mitotane<p>mitotane decreases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>moxisylyte<p>moxisylyte and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nabumetone<p>benazepril increases toxicity of nabumetone by unspecified interaction mechanism. Use Caution/Monitor. Combination may result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>nadolol<p>nadolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>naproxen<p>benazepril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>nebivolol<p>nebivolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nesiritide<p>nesiritide, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.</p></li><li>nicardipine<p>amlodipine and nicardipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nifedipine<p>amlodipine and nifedipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nisoldipine<p>amlodipine and nisoldipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nitroglycerin iv<p>nitroglycerin iv, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.</p></li><li>nitroglycerin po<p>nitroglycerin po, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. monitor blood pressure.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, amlodipine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. Observe for possible additive hypotensive effects during concomitant use. .<span><br><br></span>nitroglycerin rectal, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>nitroglycerin sublingual<p>amlodipine, nitroglycerin sublingual.
Either increases toxicity of the other by additive vasodilation. Modify Therapy/Monitor Closely. Marked orthostatic hypotension reported with concomitant use.</p></li><li>nitroglycerin transdermal<p>nitroglycerin transdermal, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.</p></li><li>nitroprusside sodium<p>nitroprusside sodium, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.<span><br><br></span>amlodipine increases effects of nitroprusside sodium by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>obinutuzumab<p>obinutuzumab increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Obinutuzumab may enhance the hypotensive effect of blood pressure lowering agents.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider dose reduction for amlodipine.</p></li><li>olanzapine<p>olanzapine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease dose of calcium channel blocker; dose of amlodipine should be decreased by at least 50%; clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. if such events occur, consider further dose reduction of  calcium channel blocker or switching to alternative to calcium channel blocker <span><br><br></span>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of amlodipine by  altering metabolism. Modify Therapy/Monitor Closely. Decrease dose of calcium channel blocker; dose of amlodipine should be decreased by at least 50%; clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. if such events occur, consider further dose reduction of  calcium channel blocker or switching to alternative to calcium channel blocker </p></li><li>oxaprozin<p>benazepril, oxaprozin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>paliperidone<p>paliperidone increases toxicity of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.<span><br><br></span>benazepril increases toxicity of paliperidone by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>penbutolol<p>penbutolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>pentobarbital<p>pentobarbital, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>pentoxifylline<p>pentoxifylline, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>phendimetrazine<p>phendimetrazine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>phenelzine<p>phenelzine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>phenobarbital<p>phenobarbital, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>phenoxybenzamine<p>benazepril, phenoxybenzamine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.<span><br><br></span>phenoxybenzamine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>phentermine<p>phentermine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>phentolamine<p>phentolamine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>phentolamine<p>benazepril, phentolamine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>pindolol<p>pindolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>piroxicam<p>benazepril, piroxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>potassium acid phosphate<p>benazepril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.<span><br><br></span>potassium acid phosphate and benazepril both increase  serum potassium. Use Caution/Monitor. Potassium salts may increase the hyperkalemic effects of ACE inhibitors; the effect may be the result of aldosterone suppression in patients receiving ACE inhibitors</p></li><li>potassium chloride<p>benazepril increases levels of potassium chloride by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.<span><br><br></span>potassium chloride and benazepril both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium citrate<p>benazepril increases levels of potassium citrate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.<span><br><br></span>potassium citrate and benazepril both increase  serum potassium. Use Caution/Monitor. Potassium salts may increase the hyperkalemic effects of ACE inhibitors; the effect may be the result of aldosterone suppression in patients receiving ACE inhibitors</p></li><li>potassium citrate/citric acid<p>benazepril and potassium citrate/citric acid both increase  serum potassium. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>potassium iodide<p>potassium iodide and benazepril both increase  serum potassium. Use Caution/Monitor. Potassium salts may increase the hyperkalemic effects of ACE inhibitors; the effect may be the result of aldosterone suppression in patients receiving ACE inhibitors</p></li><li>potassium phosphates, iv<p>benazepril and potassium phosphates, iv both increase  serum potassium. Use Caution/Monitor. Increased risk of hyperkalemia.</p></li><li>prazosin<p>benazepril, prazosin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.<span><br><br></span>prazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>propofol<p>propofol, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>propranolol<p>propranolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>quetiapine<p>quetiapine increases toxicity of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.<span><br><br></span>benazepril increases toxicity of quetiapine by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>rasagiline<p>rasagiline, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>riociguat<p>riociguat, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>risperidone<p>risperidone, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>ropivacaine<p>ropivacaine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>salsalate<p>benazepril, salsalate.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>saquinavir<p>saquinavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>saxagliptin<p>saxagliptin increases toxicity of benazepril by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Increased risk of adverse/toxic effects, specifically increased risk of angioedema.</p></li><li>secobarbital<p>secobarbital, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>selegiline<p>selegiline, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>sevoflurane<p>sevoflurane, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.</p></li><li>sildenafil<p>sildenafil, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>silodosin<p>benazepril, silodosin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.<span><br><br></span>silodosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>simeprevir<p>simeprevir increases levels of amlodipine by decreasing metabolism. Modify Therapy/Monitor Closely. May result in increased plasma concentrations of calcium channel blockers due to intestinal CYP3A4 and/or P-gp inhibition by simeprevir.</p></li><li>sirolimus<p>benazepril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>sitagliptin<p>sitagliptin increases toxicity of benazepril by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Increased risk of adverse/toxic effects, specifically, increased risk of angioedema.</p></li><li>sodium bicarbonate<p>sodium bicarbonate decreases effects of benazepril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid decreases effects of benazepril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>sotalol<p>sotalol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>spironolactone<p>benazepril and spironolactone both increase  serum potassium. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sulfasalazine<p>sulfasalazine decreases effects of benazepril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>benazepril, sulfasalazine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>sulindac<p>benazepril, sulindac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>tacrolimus<p>amlodipine will increase the level or effect of tacrolimus by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Adjust dose when appropriate.</p></li><li>tadalafil<p>tadalafil increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.<span><br><br></span>tadalafil increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>telaprevir<p>telaprevir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Exposure to amlodipine was increased when co-administered with telaprevir. Caution should be used and dose reduction for amlodipine should be considered. Clinical monitoring is recommended.</p></li><li>temsirolimus<p>benazepril, temsirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>terazosin<p>benazepril, terazosin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.<span><br><br></span>terazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>timolol<p>timolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>tolazamide<p>benazepril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tipranavir<p>tipranavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor.</p></li><li>tolbutamide<p>benazepril increases effects of tolbutamide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tolmetin<p>benazepril, tolmetin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>torsemide<p>benazepril, torsemide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>triamterene<p>benazepril and triamterene both increase  serum potassium. Use Caution/Monitor.</p></li><li>trimagnesium citrate anhydrous<p>trimagnesium citrate anhydrous, amlodipine.
Either increases effects of the other by Other (see comment). Use Caution/Monitor. 
Comment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness.</p></li><li>trimethoprim<p>trimethoprim and benazepril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>vardenafil<p>vardenafil, benazepril.
Either increases effects of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>verapamil<p>amlodipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole increases levels of amlodipine by decreasing metabolism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>yohimbine<p>yohimbine decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Yohimbine may diminish the antihypertensive effect of antihypertensive agents.</p></li><li>ziprasidone<p>ziprasidone, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>zotepine<p>zotepine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.<span><br><br></span>benazepril, zotepine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li>